Feature | February 19, 2014

Experimental Wireless Messaging Technology Remotely Monitors Patient Heart Conditions

LAPTOP-HF Telecardiology Remote Patient Monitoring ICM EP Lab Heart Failure ECG

February 19, 2014 — A new treatment option for heart disease is being tested at The University of Kansas Hospital that could be significant in telemedicine. Using an implantable monitoring device, the patient can hold a smartphone-type device to the chest and the device will relay info wirelessly from the heart implant to the doctors at the hospital. It allows doctors the ability to better personalize treatment for heart failure patients while giving those patients more control of their chronic condition.

The clinical trial is called LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy.) Dhanunjaya Lakkireddy, an electrophysiologist at The University of Kansas Hospital, said the LAPTOP-HF monitor can give heart patients and their doctors critical information immediately. 

"Before this device, any of these measurements had to be taken here in our office. Now with this technology, we can obtain the information from the patient's home," Lakkireddy said. "It's especially helpful for patients who live a long way from us. We can constantly monitor their condition and give them medication changes any time, rather than waiting for a scheduled appointment."

That's a huge benefit for Larry Stewart, who lives nearly two hours south of the hospital in Bronson, Kan. Before enrolling in the trial, Stewart and his wife had to make the journey to see Lakkireddy about every six weeks for congestive heart failure and atrial fibrillation.

Now, after having the device (which looks like a pacemaker) surgically implanted in his chest, all Stewart has to do each day is hold the small monitor (the size of a smartphone) up to his chest and the readings are electronically sent back to the doctor's office for instant analysis. 

"It makes me feel better that there's something there that's measuring and keeping an eye on my heart," Stewart said. 

It also means only making the trip to the doctor's office every three months, while still being monitored regularly, which is especially helpful during winter months when road conditions can be dangerous. 

St. Jude Medical developed the monitor. The University of Kansas Hospital is among the 75 sites in the United States chosen to evaluate the safety and effectiveness of the device.

For more information: www.kumed.com

Related Content

CardioKinetix, Parachute device, heart failure, 500th implantation, PARACHUTE IV Trial
News | Heart Failure| July 22, 2016
CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning...
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Dictum Health, telehealth study, IDM100 tablet, neonate cardiology, in-home monitoring
Technology | Telecardiology| July 19, 2016
Dictum Health Inc. announced the launch of a post-U.S. Food and Drug Administration (FDA)-approval study of its end-to-...
SunTech Medical, SunTech CT40 sot-check vital signs device, FDA approval
Technology | Peripheral Arterial Disease (PAD)| July 18, 2016
Blood pressure technology company SunTech Medical received U.S. Food and Drug Administration (FDA) approval for...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 12, 2016 | Heidi Olsen, Pharm.D
With the recent introduction of several novel oral...
University of Guelph study, heart failure risk, gender, aging
News | Heart Failure| July 08, 2016
University of Guelph researchers have uncovered a possible clue as to why women have lower rates of heart failure than...
Abbott, FIRM-guided rotor ablation, atrial fibrillation, clinical studies, Cardiostim 2016
News | EP Mapping and Imaging Systems| July 07, 2016
July 7, 2016 — Abbott recently announced positive results from three clinical studies investigating the benefits asso
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
AtriCure, AtriClip PRO2 LAA Exclusion System, CE Mark, left atrial appendage occlusion
News | Left Atrial Appendage (LAA) Occluders| July 05, 2016
AtriCure Inc. announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System...
Overlay Init